ChiCTR2200065258 版本V1.1 版本创建时间2023/04/28 20:08:27 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2200065258 

最近更新日期:

Date of Last Refreshed on:

2022-11-01 17:34:13 

注册时间:

Date of Registration:

2022-11-01 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

戊乙奎醚预防妇科腹腔镜手术术后恶心和呕吐:一项随机、双盲、对照试验

Public title:

penehyclidine for prevention of postoperative nausea and vomitting in patients undergoing gynecological laparoscopic surgery: a randomized, double-blind, controlled trial

注册题目简写:

English Acronym:

研究课题的正式科学名称:

戊乙奎醚预防妇科腹腔镜手术术后恶心和呕吐:一项随机、双盲、对照试验

Scientific title:

penehyclidine for prevention of postoperative nausea and vomitting in patients undergoing gynecological laparoscopic surgery: a randomized, double-blind, controlled trial

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

赵凯 

研究负责人:

王胜 

Applicant:

Zhao Kai 

Study leader:

Wang Sheng 

申请注册联系人电话:

Applicant telephone:

19826091630

研究负责人电话:

Study leader's
telephone:

19156007726

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1416488784@qq.com

研究负责人电子邮件:

Study leader's E-mail:

iamsheng2006@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

安徽省合肥市庐阳区庐江路17号

研究负责人通讯地址:

安徽省合肥市庐阳区庐江路17号

Applicant address:

17 Lujiang Road, Luyang District, Hefei, Anhui, China

Study leader's address:

17 Lujiang Road, Luyang District, Hefei, Anhui, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

中国科学技术大学附属第一医院(安徽省立医院)

Applicant's institution:

The First Affiliated Hospital of University of Science and Technology of China

研究负责人所在单位:

中国科学技术大学附属第一医院(安徽省立医院)

Affiliation of the Leader:

The First Affiliated Hospital of University of Science and Technology of China

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2022KY伦审第245号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中国科学技术大学附属第一医院医学研究伦理委员会

Name of the ethic committee:

Medical Research Ethics Committee of the First Affiliated Hospital, University of Science and Technology of China

伦理委员会批准日期:

Date of approved by ethic committee:

2022-10-09 00:00:00

伦理委员会联系人:

沈佐君

Contact Name of the ethic committee:

Shen Zuojun

伦理委员会联系地址:

安徽省合肥市庐江路17号安徽省立医院行政楼6楼

Contact Address of the ethic committee:

6th Floor, Administration Building, Anhui Provincial Hospital, 17 Lujiang Road, Hefei, Anhui, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 551 62282931

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

中国科学技术大学附属第一医院(安徽省立医院)

Primary sponsor:

The First Affiliated Hospital of University of Science and Technology of China

研究实施负责(组长)单位地址:

安徽省合肥市庐阳区庐江路17号

Primary sponsor's address:

17 Lujiang Road, Luyang District, Hefei, Anhui, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

安徽

市(区县):

合肥

Country:

China

Province:

Anhui

City:

Hefei

单位(医院):

中国科学技术大学附属第一医院(安徽省立医院)

具体地址:

安徽省合肥市庐阳区庐江路17号

Institution
hospital:

The First Affiliated Hospital of University of Science and Technology of China

Address:

17 Lujiang Road, Luyang District, Hefei, Anhui, China

经费或物资来源:

中国科学技术大学附属第一医院(安徽省立医院)

Source(s) of funding:

The First Affiliated Hospital of University of Science and Technology of China

研究疾病:

妇科腹腔镜手术  

Target disease:

gynecological laparoscopic surgery

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

本研究主要目的是将盐酸戊乙奎醚(长托宁)用于妇科腹腔镜手术人群,观察长托宁对患者在恶心呕吐的影响,探索长托宁围术期能否实现改善PONV,提高患者围术期满意度及舒适度  

Objectives of Study:

The main purpose of this study is to use penehyclidine hydrochloride in gynecological laparoscopic surgery population, observe the effect of penehyclidine on nausea and vomiting of patients, explore whether penehyclidine can improve PONV during perioperative period, and improve the satisfaction and comfort of patients during perioperative period

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

①ASA分级Ⅰ-Ⅲ级;②年龄≥18岁;③BMI≦35kg/m2;④妇科腹腔镜手术。

Inclusion criteria

①ASA Ⅰ-Ⅲ; ② Age ≥18 years; (3) BMI ≦ 35 kg/m2; ④ Gynecological laparoscopic surgery.

排除标准:

①术前应用抗胆碱类药物;②患者不能理解各类量表评分条目;③有神经、精神类疾病史;④有严重心、肺、肝、肾功能障碍;⑤青光眼、重症肌无力;⑥既往肺部手术史;⑦术前放化疗;⑧三个月内参加过其他药物试验。

Exclusion criteria:

① preoperative use of anticholinergic drugs; ② Patients could not understand the scoring items of various scales; ③ History of neurological and psychiatric diseases; (4) Severe heart, lung, liver and renal dysfunction; Glaucoma and myasthenia gravis; ⑥ Previous pulmonary surgery history; ⑦ preoperative chemoradiotherapy; Participated in other drug trials within 3 months.

研究实施时间:

Study execute time:

From 2022-11-10 00:00:00 To 2024-09-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2022-11-01 00:00:00 To 2024-09-30 00:00:00

干预措施:

Interventions:

组别:

戊乙奎醚组

样本量:

47

Group:

penehyclidine group

Sample size:

干预措施:

麻醉诱导时与术后静脉镇痛泵中使用戊乙奎醚

干预措施代码:

Intervention:

Penehycliane was used in anesthesia induction and postoperative intravenous analgesic pump

Intervention code:

组别:

安慰剂组

样本量:

47

Group:

The placebo group

Sample size:

干预措施:

麻醉诱导时与术后静脉镇痛泵中给予同等剂量生理盐水

干预措施代码:

Intervention:

The same dose of normal saline was administered during anesthesia induction and postoperative intravenous analgesia pump

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

安徽省 

市(区县):

合肥市 

Country:

China

Province:

Anhui

City:

Hefei

单位(医院):

中国科学技术大学附属第一医院(安徽省立医院) 

单位级别:

三甲 

Institution
hospital:

The First Affiliated Hospital of University of Science and Technology of China

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

PONV发生率

指标类型:

主要指标

Outcome:

The incidence of PONV

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后恶心严重程度、呕吐率、抢救性止吐药的种类与剂量、术后24h、48h时舒适度(Kolcaba的舒适状况量表)和恢复质量(QoR-15)

指标类型:

次要指标

Outcome:

Severity of postoperative nausea, vomiting rate, type and dose of rescue antiemetics,Comfort (Kolcaba's Comfort Scale) and quality of recovery (QoR-15) at 24h and 48h after operation

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age years

性别:

女性

Gender:

Female

随机方法(请说明由何人用什么方法产生随机序列):

①纳入病例以1:1的比例进入两组; ②使用计算机生成的随机数字表进行随机化。

Randomization Procedure (please state who generates the random number sequence and by what method):

① The included cases were divided into the two groups at a ratio of 1:1. ② Randomization is carried out using a random number table generated by computer.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

受试者、试验设计人员、试验实施人员、数据采集人员、数据分析人员均设盲。

Blinding:

Subjects, trial designers, trial implementors, data collectors, and data analysts were blinded.

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

在试验结束后可通过作者获取

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

At the end of the trial it is available through the author

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

中国科学技术大学附属第一医院(安徽省立医院)HIS系统及数据采集自制量表,SPSS20.0进行数据管理

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital) HIS system and data collection self-made scale, SPSS20.0 for data management

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2022-11-01 17:33:45